Overweight black Americans are two to three times more likely than heavy white Americans to say they are of average weight — even after being diagnosed as overweight or obese by their doctors, according to a study led by Dana-Farber Cancer Institute researchers.
The early stages of coronary artery disease in young smokers can be reversed quickly if they choose to put out their cigarettes for good, according to a positron emission tomography (PET) imaging study in the December Journal of Nuclear Medicine.
Screening children for risk factors associated with cardiovascular disease can help identify parents at risk for the condition, providing an opportunity for medical intervention in both children and their parents, according to research at Children’s Hospital of Pittsburgh of UPMC.
Scientists have discovered that mutations in a gene known as SOS1 account for many cases of Noonan syndrome (NS), a common childhood genetic disorder which occurs in one in 1,000-2,500 live births. NS is characterized by short stature, facial abnormalities and learning disabilities, as well as heart problems and predisposition to leukemia.
Physicians who once treated mainly elderly patients for health problems such as diabetes, heart disease and stroke are seeing increasingly younger patients who have the same ailments.
A survey conducted anonymously for Reuters Primary Research revealed that the cardiologists are ready to embrace medicines like statins that raise levels of good cholesterol HDL to reduce the risk of coronary artery diseases.
Magnets may interfere with the operation of pacemakers and implantable cardioverter defibrillators, according to a study published in the December 2006 edition of Heart Rhythm.
British scientists have discovered that red wines from the two regions — Sardinia and Pyrenees — boast the highest concentrations of a chemical that underlies the drink’s well-publicised benefits for cardiovascular health. The new study, published in the journal Nature.
Scientists at Wake Forest University Baptist Medical Center and colleagues at four other medical centers have launched a $10 million multi-year study to identify genes that may contribute to early atherosclerosis.
Barr Pharmaceuticals, Inc. (NYSE: BRL) and its subsidiary PLIVA d.d. (LSE: PLVD; ZSE: PLVA-R-A) today announced that PLIVA has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) to manufacture and market Pravastatin Tablets 10mg, 20mg, and 40mg, the generic version of Bristol-Myers Squibb’s PRAVACHOL(R) (Pravastatin Sodium) Tablets. The Company plans to launch its product immediately. PLIVA has also received tentative approval for its Pravastatin Tablets 80mg strength and plans to launch this strength following the expiration of a competitor’s 180-day generic drug exclusivity period and subsequent final approval of PLIVA’s application.